Monitor for updates on feasibility results and any subsequent regulatory or commercial agreements. The stock may see speculative volatility around the press conference webcast today at 10:30 a.m. ET, but the lack of FDA clearance and early-stage nature of the collaboration limit fundamental impact.
Price Chart
Executive Summary
Co-Diagnostics announced a collaboration with ReadyGo Diagnostics to evaluate blood-based molecular testing on the Co-Dx PCR platform, starting with decentralized Ebola detection. The collaboration is early-stage feasibility work with no guarantee of commercial success, and the Co-Dx platform itself has not received FDA clearance. This is a non-financial, pre-revenue development milestone with no near-term revenue impact.
Key Facts
- Co-Diagnostics and ReadyGo Diagnostics are collaborating to evaluate blood-based molecular testing at the point of need, starting with Ebola.
- The collaboration will assess compatibility of ReadyGo's GoCollect sample-preparation technology with the Co-Dx PCR platform.
- The Co-Dx PCR platform has not been cleared or authorized by the FDA and is not yet available for sale.
- Feasibility work has begun; there is no assurance the evaluation will be successful or result in a commercial product.
- The WHO reported 6,757 confirmed Ebola cases and 3,267 deaths in the DRC outbreak as of Sept 7, 2026.
Financial Impact
No financial terms or revenue figures disclosed; collaboration is early-stage feasibility work.
Risk Factors
- Feasibility evaluation may fail or be delayed, resulting in no commercial product.
- Co-Dx PCR platform requires FDA clearance before any product can be sold.
- No financial terms disclosed; collaboration may not lead to material revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-042844 |
| Exhibit: ex99-1.htm | 0001493152-26-042844 |
| Document: 0001493152-26-042844-index-headers.html | 0001493152-26-042844 |
| Document: 0001493152-26-042844-index.html | 0001493152-26-042844 |
| Document: 0001493152-26-042844.txt | 0001493152-26-042844 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5473 | awaiting T+20 | — | $0.4690 (+14.31%) |
Oct 15, 2026 12d ago | 8-K/A | $0.7151 | awaiting T+20 | — | $0.4690 (+34.41%) |
Oct 13, 2026 14d ago | 8-K | $1.07 | awaiting T+20 | — | $0.4690 (+55.96%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.4690 (−50.15%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.4690 (−50.15%) |
Sep 4, 2026 7w ago | DEFA14A | $1.16 $1.10 | ▼ −5.17% | ▼ −5.77% | $0.4690 (−59.57%) |
Sep 2, 2026 8w ago | EFFECT | $1.16 $1.07 | ▲ +7.76% | ▲ +7.68% | $0.4690 (+59.57%) |
Jul 31, 2026 12w ago | 8-K | $1.44 $1.21 | ▲ +15.97% | ▲ +18.96% | $0.4690 (+67.43%) |
Jul 27, 2026 13w ago | 424B5 | $1.41 $1.23 | ▲ +12.77% | ▲ +16.15% | $0.4690 (+66.74%) |
Jun 1, 2026 21w ago | EFFECT | $6.20 $3.10 | ▲ +50.00% | ▲ +48.70% | $0.4690 (+92.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers